Texas Nurse Loses DEA Power – No More Controlled Prescriptions
Published Date: 3/27/2025
Notice
Summary
Joely Keen, a nurse practitioner from Texas, lost her DEA registration because she no longer has the legal right to handle controlled substances in Texas. This means she can’t prescribe or manage certain medications anymore. The decision is final, effective immediately, and impacts her ability to work with controlled drugs, with no money penalties mentioned.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Joely Keen
The Drug Enforcement Administration revoked DEA Certificate of Registration No. MK4402210 issued to Joely Keen, A.P.R.N. Because her Texas APRN and registered nurse licenses are revoked and she lacks prescriptive authority, she cannot prescribe, administer, dispense, or otherwise handle controlled substances in Texas. The Order is effective April 28, 2025, and no monetary penalties are mentioned.
Pending Renewal and New Applications Denied
The Order denies any pending applications of Joely Keen to renew or modify DEA registration No. MK4402210 and denies any other pending application for additional DEA registration in Texas. This denial is made pursuant to 21 U.S.C. 823(g)(1) and 824(a) and is part of the revocation action effective April 28, 2025.
Opportunity to Seek Reconsideration
The Order notes that Respondent may dispute the factual finding that she lacks a Texas license by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and responses must be filed and served by email as specified.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Previous / Next Documents
Previous: 2025-05163, Thomas Andr'e Endicott, D.D.S.; Decision and Order
Thomas Andr'e Endicott, a dentist from Utah, lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t legally prescribe or manage certain drugs anymore, effective immediately.
Next: 2025-05165, Harvey Leslie, M.D.; Decision and Order
Dr. Harvey Leslie from Georgia lost his medical license earlier this year, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final, meaning he can no longer prescribe or manage these drugs. This change is immediate and affects Dr. Leslie’s ability to work with controlled medicines, with no money or appeals left on the table.